Condition: Rheumatoid Arthritis (RA) · Sponsor: Centre Hospitalier Princesse Grace
The aim of this study is to offer patients two treatment options: morning or evening administration of a JAK inhibitor prescribed within the framework of its marketing authorization, according to the EULAR response. The objective is to determine whether evening administration in our patients with rheumatoid arthritis provides greater efficacy than morning administration in our patients taking JAK inhibitors once daily.
This description comes directly from the study's public registry record.
Olivier BROCQ, MD · 97 98 99 00 · recherche.clinique@chpg.mc
Nicolas RIJO · 97 98 99 00 · recherche.clinique@chpg.mc
Always discuss trial participation with your own doctor first.
| Centre Hospitalier Princesse Grace | Monaco, Monaco | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07674134